home > ict > autumn 2019 > a decentralised ecosystem
International Clinical Trials

A Decentralised Ecosystem

Digital disruption in clinical research has been a constant for over 20 years; however, ensuring that this is still relevant where ‘the rubber hits the road’ has been a challenge (or roadblock, sticking with the metaphor). Following my recent attendance at the annual conference of the Society of Clinical Data Managers, I believe the momentum is now greater, and there is an appetite for change. This change is to how and where we capture and analyse the valuable data that are provided by human subjects who volunteer to take part in clinical trials.

Of many presentations and panel discussions, there was so much enthusiasm from inquisitive minds in our industry. While the day-to-day work of clinical research is pressurised, the professionals and experts in our industry are determined to advance processes that can improve data quality, reduce the risks on clinical trials, and improve safety and outcomes for patients, while also working to increase efficiency through cost and cycle time reductions.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
About the author

Ian O’Shaughnessy has over 22 years of experience in clinical research working at CROs. The first part of his career was spent in roles of increasing responsibility in clinical data management and programming. This included leading regional data management organisations for ICON in Europe and Asia Pacific. Since 2013, Ian has worked in the field of risk-based monitoring, developing ICON’s methodology, processes, and systems. He has worked directly with sponsor companies on early engagement and implementing risk-based clinical strategies. Ian holds a Bachelor’s in Genetics from Trinity College Dublin, Ireland, and postgraduate qualifications in Business, Management, and Information Technology.

Print this page
Send to a friend
Privacy statement
News and Press Releases

Merck Launches ADC ExpressTM Services to Accelerate Pre-clinical Conjugation Candidate Selection

• Provides rapid production of antibody drug conjugates (ADCs) for best candidate selection • Established platform technology to reliably scale target molecules • Reduces time to clinic through comprehensive ADC services from pre-clinical to commercial from a single source
More info >>

White Papers

Biosimilars In Emerging Markets: Is It A Level Playing Field?

PRA Health Sciences (PRA)

Governments, healthcare payers, and social and health reforms, combined with the increased incidence of conditions such as cancer and diabetes are paving the way for increased uptake of biologic medicines in emerging markets. However, expensive biologic medicines can be prohibitive to many patients, creating a high level of unmet clinical need. At its best, the global expansion of biosimilars can mean a robust and steady supply of existing and new drugs reaching far-flung patient populations, but localized biosimilar drug developments, especially in China and India, combined with a lack of robust pharmacovigilance systems, threaten to derail the industry by putting patient health at risk.
More info >>

Industry Events

Clinical Operations in Oncology Trials West Coast

17-18 November 2020, Hilton San Francisco Airport Bayfront

Clinical Operations in Oncology Trials West Coast will be returning this April for another 2 day event full of thought-provoking presentations, discussions and roundtables. This years' conference highlights include the high-level, interactive immuno-oncology discussion panel where specialists from Shasta Bio Ventures, Abbvie and BeiGene shared their top tips on how to run successful and impactful immuno-oncology studies.
More info >>



©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement